新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 大型合约研究机构去年增长10%

大型合约研究机构去年增长10%

来源:生物谷 2013-09-03 20:12

2013年9月3日讯 /生物谷BIOON/ --虽然医药企业现在仍然面临着研究经费的缩减,一些大型合约研究机构在2012年仍然保持着两位数的增长率。根据调查显示,2012年合约研究行业市场达到了136亿美元。一些合约研究巨头如Quintiles收入增加了12%达到了37亿美元。整个行业平均增长率达到10%。分析人士认为这应当归功于新兴市场的开发。去年CRO企业增大了在中国、印度、南美和东欧等地区的投入,如今看来显然是一步妙棋。(生物谷Bioon.com)

详细英文报道:

Despite concerns about slashed R&D budgets, overexpansion and consolidation, the titans of the CRO business are still posting double-digit growth, clocking $13.6 billion in 2012, according to a report.

That's a 10% annual revenue jump, according to GlobalData, which charted the performance of roughly 40 of the world's largest contract researchers. Much of that growth reflects a top-heavy industry, GlobalData notes, as Quintiles ($Q) and its 12.1% annual growth padded the group's total, chipping in $3.7 billion. Same goes for Covance ($CVD), which grew 4% to $2 billion last year.

But the real story is taking place in emerging markets, GlobalData said, as the top CROs increased their revenue in places like China and India by about 14.6%, outpacing global growth. That's unlikely to change anytime soon, GlobalData analyst Adam Dion said, as CROs are still scrambling to expand in high-growth geographies.

"Asia, Central and South America, as well as Eastern Europe have become attractive regions for pharmaceutical outsourcing as a result of easy access to a large number of treatments, low labor and manufacturing costs, and highly skilled medical workforces," Dion said in a statement.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库